Document is current
Any future updates will be listed below
-
Authors
Christie, Aimee J.
Bolden, Caleb
Park, Elyse R.
Yeh, Gloria Y.
O’Cleirigh, Conall
Peppercorn, Jeffrey
Denninger, John W.
Hirschberg, April M.
Lee, Hang
Markwart, Michaela
Siefring, Emma
Mizrach, Helen R.
Bullock, Andrea J.
Hall, Daniel L.
-
Funding
Funding for this research was provided by:
National Center for Complementary and Integrative Health (T32AT000051, K23AT010157, K24AT009465)
National Cancer Institute (K24CA197382)
National Center for Advancing Translational Sciences (UL1TR002541)
- License Information
-
More Information
Article History
Received: 21 May 2025
Accepted: 17 August 2025
First Online: 1 September 2025
Declarations
:
: This clinical trial had IRB approval (Dana-Farber/Harvard Cancer Center; Protocol 21–090). All procedures were monitored by the Dana-Farber Harvard Cancer Center Institutional Review Board (Protocol ID: 21–090) and an independent monitoring committee. All procedures conformed to the Declaration of Helsinki ethical standards. All participants provided electronic informed consent.
: DLH has received consultation fees from Goodpath, Inc. All other authors have no competing interests to declare.
: Not applicable. All content is original.
